Home Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection
 

Keywords :   


Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection

2016-11-13 14:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. Phase 2 Data Presentations at The Liver Meeting Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously Failed KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three Phase 2 clinical trials evaluating MK-3682B (MK-3682/grazoprevir/ruzasvir1), the companys investigational all-oral, triple-combination regimen for the treatment of chronic hepatitis C (HCV) infection (informally referred to as MK3). Language: English Contact: Media:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: or high people showing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
29.03Chinese smartphone giant takes on Tesla
29.03Questions raised over Temu cash 'giveaway' offer
29.03Charge of 90 to clear problem debt axed for poorest
29.03India's army of gold refiners face new competition
28.03Amorepacific Patents Hair Growth Compositions with Camellia Kaempferol Glycoside
28.03Dry Shampoo That Provides Color Patented by Church & Dwight
28.03FTX's Sam Bankman-Fried sentenced to 25 years
28.03Pork producers donate 35,000 pounds of Dailys bacon to Utah Food Bank
More »